The anti-cancer principle of Serpatinib

Sepretinib, also known as serpatinib, is a highly effective and innovative targeted therapy for cancers with RET gene fusions or mutations. Its unique mechanism of action has injected new vitality into the field of cancer treatment. Seputinib is used not only to treat certain types of non-small cell lung cancer, but also to treat certain types of thyroid cancer in adults and children over 2 years old.

As an orally bioavailable, selective inhibitor of wild-type, mutant and fusion productsRET, a proto-oncogene receptor tyrosine kinase that may undergo rearrangement during transfection. Through oral administration, seputinib can precisely bind and target multiple RET mutants and RET-containing fusion products, thereby inhibiting tumor cells that overgrow due to enhanced RET activity.

Overexpression, activating mutations and fusions of RET may lead to the upregulation or overactivation of RET tyrosine kinase activity in various cancer cells. This dysregulation of RET activity plays a central role in the occurrence and development of various cancers. The high selectivity of seputinib enables it to attack these targets more accurately, thereby reducing damage to healthy cells and significantly improving the safety of the treatment and patient tolerance.

Although Seputinib has been launched in the domestic market, unfortunately, it has not yet been included in the scope of medical insurance reimbursement. Currently, the version sold in China is 80mg, with a total of 56 pills, and the price is about 15,000 yuan. At the same time, overseas markets also provide original and generic versions of Seputinib, but the price of the original version is relatively high. Patients in need can purchase the original version of Seputinib directly from pharmacies in domestic hospitals. In addition, there is also a generic version of Seputinib on the market in Laos, with a specification of 40 mg and a total of 120 tablets, and the price is about more than 4,000 yuan. If you have more questions about seputinib or require further consultation, it is recommended that you contact a professional overseas medical consultant.

In summary, seputinib effectively inhibitsRET kinase activity exerts its anti-tumor effects, providing a new therapeutic strategy for cancer patients affected by RET gene fusions or mutations. With continued in-depth research into the mechanism of action of this drug, we have reason to expect that more cancer patients will benefit from it in the future.